Sanofi-Aventis extends Genzyme offer deadline
This article was originally published in Scrip
Sanofi-Aventis is proving to be a determined suitor as it has extended for a second time the deadline for Genzyme shareholders to accept a $69 a share offer. While acknowledging that discussions are in place to broker a contingent value right (CVR) involving Lemtrada (alemtuzumab MS) as an element of any potential transaction, it is clear that there is still a disconnect between the price Genzyme shareholders are willing to accept and Sanofi-Aventis is willing to offer.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.